Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
Business Wire - 2024-04-15T17:40:06.573Z

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disord Read this story

Related Articles

ZoomInfo to Report Financial Results for First Quarter 2024 on May 7, 2024
by Yahoo Finance
JPMorgan Chase Reports First-Quarter 2024 Financial Results
by Yahoo Finance
State Street Corporation (NYSE: STT) Reports First-Quarter 2024 Financial Results
by Yahoo Finance

MarineMax to Report Second Quarter Fiscal 2024 Financial Results on Thursday, April 25, 2024
by Yahoo Finance
UnitedHealth Group Reports First Quarter 2024 Results
by UnitedHealth Group
More Related Articles

Latest in News

Higher Ground: Community Science Unifies Us Around Climate Change
by WNYC
Weege Show: Jason Weigandt talks Nashville Supercross with Chase Sexton
by Racer X
An Alabama prison warden is arrested on drug charges
by ABC News - Breaking News, Latest News and Videos

'Pulp Fiction' 30th anniversary reunion: John Travolta, Samuel L. Jackson, Uma Thurman, more
by USA Today
New York AG Letitia James asks judge to void Trump's bond in his civil fraud verdict
by NBC News
Terry Pegula exploring selling 25% minority-stake ownership in Buffalo Bills, per report
by Buffalo Rumblings

More from Business Wire | Marinus Pharmaceuticals Inc. Pharmaceutical industry Nasdaq